In his newest column, Sarfaraz K. Niazi, PhD, looks into the domestic and international support for removing interchangeability for biosimilars in the United States.
Only the United States has 2 classes of biosimilars, one that has no clinically meaningful difference with the reference product and the other interchangeable biosimilar that undergo additional extensive testing. Both are tested the same way yet get awarded different statuses, a practice that has greatly damaged the adoption of biosimilars in the US.[1] (Figure 1).
Removing interchangeability is supported by several arguments:[2]
To remove the interchangeability status, Senator Lee has introduced a bill in the Senate that modifies the language in the BPCIA. The passage of this bill will bring the FDA in concordance with the rest of the regulatory agencies, remove misconceptions about biosimilars and expedite the adoption of biosimilars. In addition, biosimilars can also be switched with other biosimilars, and both the European Medicines Agency[4] and the United Kingdom’s Medicines and Healthcare products Regulatory Agency[5] have issued specific clarifications removing all interchangeable designations. No other global regulatory agency offers interchangeability; it is treated like any other drug, where the prescriber decides whether to substitute.
I invite my colleagues and stakeholders to write to me to add to or question the conclusions drawn in this article at niazi@niazi.com.
References
[1] Biosimilar info sheet. FDA. Accessed December 13, 2022. https://www.fda.gov/media/154917/download
[2] Niazi SK. No two classes of biosimilars: urgent advice to the US Congress and the FDA. J Clin Pharm Ther. 2022;47(9):1352-1361. doi:10.1111/jcpt.13743
[3] Biosimilar product information. FDA. Updated December 7, 2022. Accessed December 13, 2022. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
[4] Biosimilar medicines can be interchanged. EMA. September 19, 2022. Accessed December 13, 2022. https://www.ema.europa.eu/en/news/biosimilar-medicines-can-be-interchanged
[5] Guidance on the licensing of biosimilar products. United Kingdom’s MHRA. November 7, 2022. Accessed December 13, 2022. https://www.gov.uk/government/publications/guidance-on-the-licensing-of-biosimilar-products/guidance-on-the-licensing-of-biosimilar-products
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.